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Abstract
The global antimicrobial resistance surveillance system (GLASS) was launched by the
World Health Organization (WHO) in 2015. GLASS is a surveillance system for clinical spec-
imens that are sent to microbiology laboratory for clinical purposes. The unique feature of
GLASS is that clinical data is combined with microbiological data, and deduplication of the
microbiological results is performed. The objective of the study was to determine feasibility
and benefit of GLASS for surveillance of blood culture specimens. GLASS was imple-
mented at Siriraj Hospital in Bangkok, Thailand using a locally developed web application
program (app) to transfer blood culture specimen data, and to enter clinical data of patients
with positive blood culture by infection control nurses and physicians via the app installed in
their smart phones. The rate of positive blood culture specimens with true infection was
15.2%. Escherichia coli was the most common cause of bacteremia. Secondary bacter-
emia, primary bacteremia, and central line-associated blood stream infection was observed
in 61.8%, 30.6%, and 12.6% of cases, respectively. Sepsis was observed in 56.9% of
patients. E.coli was significantly more common in community-acquired bacteremia, whereas
Klebsiella pneumoniae, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus
aureus, and Acinetobacter baumannii were significantly more common in hospital-acquired
bacteremia. Hospital-acquired isolates of E.coli, K.pneumoniae, A.baumannii, P.aerugi-
nosa, S.aureus and Enterococcus faecium were more resistant to antibiotics than commu-
nity-acquired isolates. In-hospital mortality was significantly higher in patients with antibiotic-
resistant bacteremia than in patients with antibiotic non-resistant bacteremia (40.5% vs.
28.5%, p<0.001). The patients with antibiotic-resistant bacteremia consumed more
resources than those with antibiotic non-resistant bacteremia. Blood culture results com-
bined with patient clinical data were shown to have more benefit for surveillance of antimi-
crobial resistance, and to be more applicable for developing local antibiotic treatment
guidelines for patients suspected of having bacteremia. However, GLASS consumed more
time and more resources than the conventional laboratory-based surveillance system.
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Introduction
Antimicrobial resistance (AMR) is a continually evolving public health crisis all over the
world. The annual AMR burden in Thailand is estimated to be 100,000 new AMR infections,
additional 3 million days of hospital stay, and 30,000 deaths [1]. The annual cost of AMR infec-
tions in Thailand is estimated to be US$ 200 million for antibiotics and US$ 13,000 million or
0.6% of GDP for total economic loss [1]. Reported estimated AMR burden figures include hos-
pital-acquired AMR infections, but they do not include community-acquired AMR infections
[2–4]. It is projected that there will be 10 million AMR-related deaths each year and a 3%
annual reduction in world GDP by 2050 if effective containment of AMR at a global level is
not effectively implemented [5].
AMR surveillance is one of the pillars of the World Health Organization’s (WHO) 2015 global
action plan on AMR [6]. Similar to the system at our center, a laboratory-based AMR surveillance
system is used at most healthcare facilities. Limitations of conventional AMR surveillance include
the following: 1) the nature of the grown organism (causative agent, colonizer, or contaminant) is
usually undetermined; 2) the source of infection is usually absent; 3) the type of infection (com-
munity-acquired or hospital-acquired infection) is usually unavailable; and, 4) data from the same
patient who has the same isolated organisms with same antibiotic susceptibility profiles are often
duplicated in the annual report of isolated organisms and their antibiotic susceptibility. As such,
the laboratory-based AMR surveillance system model does not provide information regarding the
extent of AMR in a given population, and the data produced by this system has limited value for
developing antibiotic guidelines for patients with a specific type of infection.
Global antimicrobial resistance surveillance system (GLASS) was launched by WHO in
2015, and the manual for early implementation of GLASS in human infections is available [7].
GLASS is a case finding strategy that evaluates priority specimens that are routinely sent to lab-
oratory for clinical purposes. Priority specimen types include blood, urine, feces, and urethral
and cervical swabs. The benefit of GLASS is that clinical data is combined with microbiological
data, and deduplication of the microbiological results is performed in order to eliminate dupli-
cate copies of repeating data. Another potential benefit is that supplementary clinical informa-
tion (e.g., morbidity, mortality, and cost), intervention outcomes, and potential drivers of
AMR can be collected upon availability of resources. GLASS facilitates the monitoring AMR
trends and the development of antibiotic guidelines for specific types of infection may be supe-
rior to laboratory-based AMR surveillance. However, GLASS may require more time and
resources to collect clinical data, and to combine the clinical data with microbiological data.
Stepwise implementation of GLASS began at Siriraj Hospital in June 2016. Surveillance of
blood culture specimens was implemented first, followed by feces, sputum, and urine speci-
mens. The aim of GLASS implementation was to determine the feasibility and benefit of
GLASS at a 2,300-bed tertiary care university hospital in Thailand. We reported herein the
results of implementing GLASS for surveillance of blood culture specimens in patients who
had their blood culture samples collected for clinical purposes.
Patients and methods
This study protocol was approved by the Siriraj Institutional Review Board (SiIRB), Mahidol
University, Thailand. The consent from the study patient was waived by the SiIRB. All blood
culture specimens collected from the patients for clinical purposes during July 2016 and Febru-
ary 2017 were included. Blood culture specimens were sent to Department of Microbiology
and they were processed according the laboratory standard operating procedures using the
bioMe´rieux BacT/ALERT 3D Microbial Identification System or the BD BACTEC FX blood
culture system. The period of incubation of the blood sample was 5 days before it was
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discarded as negative culture. GLASS was implemented by using a locally developed web appli-
cation program (app) to transfer blood culture specimen data, and to enter clinical data of
patients with positive blood culture by infection control nurses and physicians at the hospital
wards via the app installed in their smart phones. The web application program has 4 parts.
Part I contains microbiology and demographic data of all patients who had blood specimens
collected for culture. The information on all blood culture specimens are transferred from the
laboratory every day, and they are managed by trained back office personnel before the results
of positive blood culture specimens are sent to the designated infection control nurses and
physicians. Part II contains clinical data of patients with positive blood cultures, including the
nature of the isolated organism (infection or contaminant), source or site of infection (primary
bacteremia, secondary bacteremia, central line-associated blood stream infection or CLABSI),
type of infection (community-acquired or hospital-acquired infection), severity of infection
(sepsis or non-sepsis), empirical antibiotics being given on the date of blood specimen collec-
tion, specific antibiotics given after the culture results were available, and clinical outcomes at
the end of antibiotic treatment. These data were collected from patient medical records or
from responsible healthcare personnel, and they were entered into the program by infection
control nurses and/or physicians via their smart phones. The average time for entering part II
information was 10 minutes. Part III contains antibiotic susceptibility results of the isolated
bacteria reported by the laboratory that were managed by trained back office personnel. Part
IV contains patient outcome data at hospital discharge and hospitalization costs that were
transferred from the hospital database.
Definitions
The isolated bacteria is considered the cause of infection or true bacteremia if the patient has
clinical features of infection compatible with the isolated bacteria, has no other causes of those
clinical features, and the responsible physician treats such recovered bacteria with antibiotic
(s). The isolated bacteria is considered contaminant if the patient has no clinical features of
infection or the isolated bacteria usually resides on the skin or environment (e.g., Bacillus spp.,
Corynebacterium spp., Propionibacterium spp.), and it is not compatible with causing the infec-
tion which the patient may have, or the responsible physician does not treat such recovered
bacteria with antibiotic which contains activity against such bacteria, or the infection resolves
without receiving antibiotic against such isolated bacteria.
Bacteremia in a patient who is hospitalized more than 2 days at Siriraj Hospital or other
hospitals prior to admission to Siriraj Hospital or has healthcare-associated conditions (e.g.
prior hospitalization within 3 months, prior use of antibiotic within 90 days, resident of long
term care facility, chronic hemodialysis) is defined as hospital-acquired infection (HAI),
whereas bacteremia in a patient who is hospitalized at Siriraj Hospital within 2 days and has
no healthcare-associated conditions (e.g. prior hospitalization within 3 months, prior use of
antibiotic within 90 days, resident of long term care facility, chronic hemodialysis) is defined
as community-acquired infection (CAI).
Primary bacteremia is defined as bacteremia with unknown source of the bacteria isolated
from blood specimen. Secondary bacteremia is defined as bacteremia in a patient with prior local-
ized infection caused by the same bacteria isolated from blood specimen. Central line-associated
blood stream infection (CLABSI) is defined as bacteremia in a patient with indwelling central
intravascular catheter without other sources of the isolated bacteria from blood specimen.
Sepsis is defined as life-threatening organ dysfunction due to bacteremia with clinical fea-
tures of organ dysfunction, such as respiration rate more than 22 per minute, alteration of con-
sciousness, systolic blood pressure less than 100 mm Hg.
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Concordant empirical antibiotic therapy refers to at least one of the given antibiotics has in
vitro activity against the isolated bacteria whereas non-concordant empirical antibiotic therapy
refers to none of the given antibiotics has in vitro activity against the isolated bacteria.
The clinical outcomes at the end of antibiotic treatment are classified as cure, superinfection
or death. The patient with true bacteremia who received antibiotic (s) is considered cure if all
clinical features of infections disappear before or at the end of antibiotic therapy. Superinfec-
tion is the infection due to other bacteria from any sites in addition to the bacteria isolated
from blood specimen in the patient with true bacteremia and receives antibiotic (s) against the
bacteria isolated from blood specimen.
Antibiotic-resistant bacteremia is defined as bacteremia caused by carbapenem-resistant or
third-generation cephalosporin-resistant E.coli, K.pneumoniae, and other Enterobacteriaceae;
carbapenem-resistant P.aeruginosa; carbapenem-resistant A.baumannii; fluoroquinolone-
resistant Salmonella spp.; methicillin-resistant S.aureus (MRSA); methicillin-resistant coagu-
lase-negative staphylococci (MRCNS); vancomycin-resistant E.faecium; and, penicillin-non-
susceptible S.pneumoniae.
Deduplication of the same bacterial isolates is performed for all episodes of bacteremia with
recovery of two or more isolates of the same bacteria. Only one isolate of the same bacteria
with the identical antibiotic susceptibility profile is included in the analysis of the rate of anti-
biotic resistance to each antibiotic.
Statistical analysis
The minimum sample size of 865 patients calculated for this study was based on an estimated
prevalence of bacteremia of 10%±2% in patients who had blood cultures collected, with a type
I error of 5%. Data are presented as number and percentage, mean ± standard deviation, or
median. Fisher’s exact test or χ2 test was used to compare categorical variables and t test to
compare quantitative variables. All statistical analyses were performed using either SPSS Statis-
tics or Microsoft Excel. A p-value of0.05 was considered statistically significant.
Results
There were 8,196 blood culture specimens from 2,825 admissions of 2,393 patients, and 1,611
isolates of organisms recovered from all blood culture specimens during July 2016 and Febru-
ary 2017.
The percentage of blood cultures positive for any organisms was 40.2% among 2,393
patients, 39.3% among 2,825 admissions, and 18.7% among 8,196 blood specimens. Organisms
isolated from all blood specimens from all admissions of all included patients are shown in
Table 1. The most common isolated organism was coagulase-negative Staphylococcus spp.
(CNS), followed by E.coli, K.pneumoniae, S.aureus, A.baumannii, and P.aeruginosa.
The percentage of blood cultures positive for bacteria was 38.8% among 2,393 patients,
37.9% among 2,825 admissions, and 18.0% among 8,196 blood specimens. The causative and
contaminant bacteria isolated from all blood specimens from all admissions of all included
patients are shown in Table 2. The contamination rate of blood cultures was 3.5% among all
blood culture specimens and 18.9% among positive blood culture specimens. The most com-
mon contaminant was CNS (86.5%). Among all isolates of CNS in blood cultures, 84.9% were
contaminants and 15.1% were causative bacteria. CNS isolates that were contaminants tended
to be more resistant to antibiotics than CNS causing infections. The percentage of blood cul-
tures with causative agents was 15.2%, with E.coli being the most common cause of bacteremia,
followed by K.pneumoniae, S.aureus, P.aeruginosa, and A.baumannii.
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Secondary bacteremia was observed in 61.8% of infection episodes, with primary bacteremia
and CLABSI being observed in 30.6% and 12.6% of infection episodes, respectively. Among 479
episodes of secondary bacteremia, the sources of bacteremia were genitourinary tract (37.2%),
respiratory tract (24.6%), gastrointestinal tract (23.0%), and musculoskeletal system (10.6%).
Among 98 episodes of CLABSI, CNS (21.4%) was the most common bacteria, followed by S.
aureus (20.4%), A.baumannii (14.3%), P.aeruginosa (13.3%), K.pneumoniae (11.2%), Enterococ-
cus faecium (9.2%), and E.coli (6.1%). Sepsis was observed in 56.9% of patients.
Comparisons between bacteremia patients with community-acquired infection (CAI) and
bacteremia patients with hospital-acquired infection (HAI) are shown in Table 3. Secondary
bacteremia was significantly more prevalent in patients with CAI. Patients with HAI were
younger and had more septic episodes. Prevalence of bacteremia due to K.pneumoniae, P.aeru-
ginosa, and A.baumannii was significantly more common in HAI. Overall prevalence of ceftri-
axone-resistant E.coli and K.pneumoniae was 19.3% in CAI, compared with 69.5% in HAI
Table 1. Organisms isolated from all blood specimens from all admissions of all included patients.
Type of organism Number of specimens with positive
culture (n = 1,530)
Number of admissions with positive
culture (n = 1,109)a
Number of patients with positive
culture (n = 963)a
Coagulase-negative
Staphylococcus spp.
291 (19.0%) 241 (21.7%) 218 (22.6%)
Escherichia coli 276 (18.0%) 226 (20.4%) 193 (20.0%)
Klebsiella pneumoniae 166 (10.8%) 131 (11.8%) 117 (12.1%)
Staphylococcus aureus 149 (9.7%) 95 (8.6%) 89 (9.2%)
Acinetobacter baumannii 111 (7.3%) 72 (6.5%) 70 (7.3%)
Pseudomonas aeruginosa 105 (6.9%) 78 (7.0%) 75 (7.8%)
Yeastsb 51 (3.3%) 37 (3.3%) 34 (3.5%)
Proteus mirabilis 39 (2.5%) 33 (3.0%) 30 (3.1%)
Enterobacter spp. 38 (2.5%) 21 (1.9%) 21 (2.2%)
Enterococcus faecium 38 (2.5%) 31 (2.8%) 31 (3.2%)
Enterococcus faecalis 35 (2.3%) 30 (2.7%) 28 (2.9%)
Salmonella spp. 28 (1.8%) 21 (1.9%) 20 (2.1%)
Stenotrophomonas maltophilia 27 (1.8%) 19 (1.7%) 19 (2.0%)
Aeromonas spp. 26 (1.7%) 20 (1.8%) 18 (1.9%)
Gram-negative rods, NF 21 (1.4%) 20 (1.8%) 18 (1.9%)
Streptococci, group D 21 (1.4%) 20 (1.8%) 14 (1.5%)
Coryneform bacteria 19 (1.2%) 17 (1.5%) 17 (1.8%)
Streptococci, beta-hemolytic 18 (1.2%) 17 (1.5%) 14 (1.5%)
Streptococci, alpha-hemolytic 15 (1.0%) 12 (1.1%) 12 (1.2%)
Bacillus spp. 14 (0.9%) 13 (1.2%) 13 (1.3%)
Micrococcus spp. 14 (0.9%) 14 (1.3%) 14 (1.5%)
Other Gram-negative bacteriac 72 (4.7%) 49 (4.4%) 46 (4.8%)
Other Gram-positive bacteriad 24 (1.6%) 22 (2.0%) 21 (2.2%)
a may have had more than one positive culture specimen
b C.tropicalis (20); C.albicans (18); C.parapsilosis complex (4); Cryptococcus neoformans (4); C.glabrata (3); C.guilliermondii (1); and, Pseudozyma spp. (1)
c Pseudomonas spp. (11); Moraxella spp. (9); Acinetobacter spp. (7); Serratia marcescens (7); Achromobacter spp. (6); Vibrio spp. (5); Burkholderia
cepacia (4); Haemophilus spp. (4); Burkholderia pseudomallei (3); Chryseobacterium spp. (3); Citrobacter spp. (3); Pastuerella spp. (2); Capnocytophaga
spp. (1); Klebsiella oxytoca (1); Methylobacterium spp. (1); Plesiomonas shigelloides (1); Proteus vulgaris (1); Providentia rettgeri (1); and, Shewanella spp.
(1)
d Enterococcus spp. (8); Streptococcus pneumoniae (7); Streptococcus suis (4); Aerococcus spp. (2); Lactococcus spp. (1); Lactobacillus spp. (1);
Peptostreptococcus spp. (1)
https://doi.org/10.1371/journal.pone.0190132.t001
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Table 2. Causative and contaminant bacteria isolated from all blood specimens from all admissions of all included patients.
Type of bacteria Causative bacteria Contaminant bacteria
Number of admissions
(n = 775)a
Number of patients
(n = 728)a
Number of admissions
(n = 251)a
Number of patients
(n = 237)a
Escherichia coli 202 (26.1%) 193 (26.5%) 0 (0%) 0 (0%)
Klebsiella pneumoniae 121 (15.6%) 117 (16.1%) 0 (0%) 0 (0%)
Staphylococcus aureus 90 (11.6%) 88 (12.1%) 1 (0.4%) 1 (0.4%)
Pseudomonas aeruginosa 75 (9.7%) 74 (10.2%) 1 (0.4%) 1 (0.4%)
Acinetobacter baumannii 69 (8.9%) 69 (9.5%) 1 (0.4%) 1 (0.4%)
Enterococcus faecium 30 (3.9%) 30 (4.1%) 1 (0.4%) 1 (0.4%)
Proteus mirabilis 30 (3.9%) 29 (4.0%) 1 (0.4%) 1 (0.4%)
Enterococcus faecalis 28 (3.6%) 28 (3.8%) 0 (0%) 0 (0%)
Coagulase-negative
Staphylococcus spp.
26 (3.4%) 25 (3.4%) 217 (86.5%) 213 (89.9%)
Enterobacter spp. 21 (2.7%) 21 (2.9%) 0 (0%) 0 (0%)
Other Gram-negative bacteria 117 (15.1%) 115 (15.8%) 4 (1.6%) 4 (1.7%)
Other Gram-positive bacteria 69 (8.9%) 67 (9.2%) 41 (16.3%) 41 (17.3%)
a may have had more than one type of bacteria
https://doi.org/10.1371/journal.pone.0190132.t002
Table 3. Comparisons between bacteremia patients with community-acquired infection and bacteremia patients with hospital-acquired infection.
Characteristic Community-acquired infection (CAI) Hospital-acquired infection (HAI) p-value
Age (years)
Mean±SD 61.6±21.3 50.5±27.2 <0.001
Median 65 57
Male gender 168/314 (53.5%) 183/321 (57.0%) 0.37
Organism
Escherichia coli 118/423 (27.9%) 86/373 (23.1%) 0.12
Klebsiella pneumoniae 51/423 (12.1%) 72/373 (19.3%) 0.005
Staphylococcus aureus 50/423 (11.8%) 39/373 (10.4%) 0.54
Pseudomonas aeruginosa 32/423 (7.6%) 44/373 (11.7%) 0.04
Acinetobacter baumannii 12/423 (2.8%) 57/373 (15.3%) <0.001
Clinical features
Primary bacteremia 121/423 (28.6%) 119/373 (31.9%) 0.31
Secondary bacteremia 298/423 (70.4%) 181/373 (48.5%) <0.001
Sepsis 216/423 (51.1%) 218/373 (58.4%) 0.04
Empirical antibiotic treatment
Concordant antibiotic therapy 341/431 (79.1%) 240/382 (62.8%) <0.001
Non-concordant antibiotic therapy 90/431 (20.9%) 142/382 (37.2%) <0.001
Length of hospital stay (days)
Mean±SD 17.9±20.0 43.6±41.0 <0.001
Median 13 29
Clinical response at the end of treatment
Response 242/333 (72.7%) 201/349 (57.6%) <0.001
Superimposed infection 43/333 (12.9%) 67/349 (19.2%) 0.03
Death 48/333 (14.4%) 81/349 (23.2%) <0.001
In-hospital mortality 79/333 (23.7%) 141/349 (40.4%) <0.001
https://doi.org/10.1371/journal.pone.0190132.t003
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(p<0.001). Methicillin-resistant S.aureus (MRSA) was significantly more common in hospital-
acquired S.aureus bacteremia, when compared with community-acquired S.aureus bacteremia
(43.2% vs. 0%, p<0.001). Concordant empirical antibiotic therapy and clinical response of
infections at the end of treatment were significantly more favorable in CAI. Length of hospital
stay and in-hospital mortality was significantly higher in HAI than in CAI (both p<0.001).
Comparisons between patients with primary bacteremia and secondary bacteremia are
shown in Table 4. E.coli and A.baumannii were significantly more common in secondary bac-
teremia, whereas K.pneumoniae was significantly more common in primary bacteremia. Pri-
mary bacteremia was significantly more prevalent in HAI. Concordant empirical antibiotic
therapy was significantly more common in primary bacteremia. Length of hospital stay, clini-
cal response of infections at the end of treatment, and in-hospital mortality were comparable
between secondary bacteremia and primary bacteremia patients. Patients with CLABSI
received more frequent non-concordant empirical antibiotic therapy, and they had a signifi-
cantly longer length of hospital stay.
Comparisons between bacteremia patients with and without sepsis are shown in Table 5.
K.pneumoniae was more common in bacteremia patients with sepsis. Clinical response of
infections at the end of treatment in bacteremia patients with sepsis was less favorable than in
bacteremia patients without sepsis. In-hospital mortality in bacteremia patients with sepsis
was significantly higher than in bacteremia patients without sepsis.
Comparisons between patients who received concordant empirical antibiotics and patients
who received non-concordant empirical antibiotics are shown in Table 6. Patients with
Table 4. Comparisons between patients with primary bacteremia and patients with secondary bacteremia.
Characteristic Primary bacteremia Secondary bacteremia p-value
Age (years)
Mean±SD 51.7±28.8 61.9±19.5 <0.001
Median 57.5 65.0
Male gender 112/188 (59.6%) 182/333 (54.7%) 0.28
Isolated bacteria
Escherichia coli 48/237 (20.3%) 149/465 (32.0%) 0.001
Klebsiella pneumoniae 50/237 (21.1%) 61/465 (13.1%) 0.006
Staphylococcus aureus 23/237 (9.7%) 48/465 (10.3%) 0.80
Pseudomonas aeruginosa 21/237 (8.9%) 41/465 (8.8%) 0.98
Acinetobacter baumannii 11/237 (4.6%) 45/465 (9.7%) 0.02
Clinical features
Community-acquired infection 128/237 (54.0%) 295/465 (63.4%) 0.02
Hospital-acquired infection 111/237 (46.8%) 166/465 (35.7%) 0.004
Sepsis 142/237 (59.9%) 255/465 (54.8%) 0.20
Empirical antibiotic treatment
Concordant antibiotic therapy 179/228 (78.5%) 305/444 (68.7%) 0.007
Non-concordant antibiotic therapy 49/228 (21.5%) 139/444 (31.3%) 0.007
Length of hospital stay (days)
Mean±SD 27.0±34.2 28.6±30.4 0.58
Median 18 19
Clinical response at the end of treatment
Response 125/204 (61.3%) 281/444 (63.3%) 0.59
Superimposed infection 32/204 (15.7%) 72/444 (16.2%) 0.86
Death 47/204 (23.0%) 91/444 (20.5%) 0.46
In-hospital mortality 70/204 (34.3%) 148/444 (33.3%) 0.81
https://doi.org/10.1371/journal.pone.0190132.t004
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S.aureus bacteremia, community-acquired infection, and primary bacteremia received concor-
dant empirical antibiotics more often; whereas, patients with A.baumannii bacteremia, hospi-
tal-acquired bacteremia, and secondary bacteremia received non-concordant empirical
antibiotics more often. Patients who received non-concordant empirical antibiotics had a lon-
ger length of hospital stay and higher in-hospital mortality than patients who received concor-
dant empirical antibiotics.
Duplicate bacterial isolates with identical antibiotic susceptibility profiles for each episode
of bacteremia were observed in 80 out of 216 isolates of E.coli, 45 out of 177 isolates of K.-
pneumoniae, 25 out of 112 isolates of A.baumannii, 25 out of 108 isolates of P.aeruginosa, 5 out
of 28 isolates of Salmonella spp., 7 out of 36 isolates of E.faecalis, 6 out of 38 isolates of E.fae-
cium, 45 out of 311 isolates of CNS, and 49 out of 149 isolates of S.aureus. Comparisons of anti-
biotic susceptibility profiles between non-duplicate isolates and duplicate isolates of the
aforementioned bacteria revealed no significant differences in antibiotic susceptibility between
non-duplicate isolates and duplicate isolates.
Comparisons of antibiotic susceptibility of common or important antibiotic-resistant bac-
teria between community-acquired and hospital-acquired bacterial isolates are shown in
Table 7. Hospital-acquired E.coli and K.pneumoniae isolates were more resistant to ceftriaxone
than community-acquired isolates. Hospital-acquired K.pneumoniae, A.baumannii, P.aerugi-
nosa isolates were more resistant to meropenem and piperacillin-tazobactam than commu-
nity-acquired isolates. None of community-acquired S.aureus isolates were MRSA whereas
Table 5. Comparisons between bacteremic patients with and without sepsis.
Characteristic Sepsis No sepsis p-value
Age (years)
Mean±SD 56.8±23.1 56.3±25.0 0.80
Median 61 61
Male gender 171/321 (53.3%) 145/263 (55.1%) 0.68
Organism
Escherichia coli 117/435 (26.9%) 86/361 (23.8%) 0.33
Klebsiella pneumoniae 78/435 (17.9%) 46/361 (12.7%) 0.04
Staphylococcus aureus 51/435 (11.7%) 40/361 (11.1%) 0.82
Pseudomonas aeruginosa 47/435 (10.8%) 29/361 (8.0%) 0.23
Acinetobacter baumannii 43/435 (9.9%) 29/361 (8.0%) 0.39
Clinical features
Community-acquired infection 225/435 (51.7%) 198/361 (54.8%) 0.38
Hospital-acquired infection 220/435 (50.6%) 168/361 (46.5%) 0.27
Primary bacteremia 142/435 (32.6%) 99/361 (27.4%) 0.12
Secondary bacteremia 265/435 (60.9%) 214/361 (59.3%) 0.64
Empirical antibiotic treatment
Concordant antibiotic therapy 334/463 (72.1%) 255/367 (69.5%) 0.40
Non-concordant antibiotic therapy 129/463 (27.9%) 112/367 (30.5%) 0.40
Length of hospital stay (days)
Mean±SD 32.5±37.5 29.7±30.0 0.36
Median 22 21
Clinical response at end of treatment
Response 215/377 (57.0%) 213/278 (76.6% <0.001
Superimposed infection 62/377 (16.5%) 44/278 (15.8%) 0.83
Death 100/377 (26.5%) 21/278 (7.6%) <0.001
In-hospital mortality 154/377 (40.9%) 54/278 (19.4%) <0.001
https://doi.org/10.1371/journal.pone.0190132.t005
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43% of hospital-acquired S.aureus isolates were MRSA. None of community-acquired E.fae-
cuim isolates were resistant to vancomycin whereas 29% of hospital-acquired E.faecuim isolates
were resistant to vancomycin.
Many bacteria on the list announced by WHO for the antibiotic-resistant bacteria consid-
ered posing the greatest threat to human health [8] were observed in this study. Carbapenem-
resistant E.coli was observed in 1.3% of E.coli isolates; carbapenem-resistant K.pneumoniae in
20.0% of K.pneumoniae isolates; carbapenem-resistant P.aeruginosa in 27.7% of P.aeruginosa
isolates; and, carbapenem-resistant A.baumannii in 69.5% of A.baumannii isolates. Vancomy-
cin-resistant enterococci (VRE) were found in 14.3% of Enterococcus spp. isolates. All VRE iso-
lates were E.faecium. MRSA was isolated from 19.0% of all S.aureus isolates. MRSA bacteremia
was 0% in community-acquired S.aureus bacteremia, but was 43% in hospital-acquired S.
aureus bacteremia.
Median length of hospital stay in all hospitalized patients with true bacteremia was 17 days.
Overall in-hospital mortality of patients with true bacteremia was 33.3%. Mortality was signifi-
cantly higher in patients with antibiotic-resistant bacteremia than in patients with antibiotic-
non-resistant bacteremia (40.5% vs. 28.5%, p<0.001) as shown in Table 8. The mortality attrib-
utable to AMR was 12.0% (95% Confidence Interval 5.7% to 18.1%). Patients with antibiotic-
resistant A.baumannii or E.faecium bacteremia had the highest mortality (66.7%). Based on
these findings from the data collected for eight months, the estimated annual number of deaths
was 194 patients with antibiotic-resistant bacteremia, and 171 patients with antibiotic-non-
resistant bacteremia.
Table 6. Comparisons between patients who received concordant empirical antibiotic therapy and patients who received non-concordant empiri-
cal antibiotic therapy.
Characteristic Concordant empirical therapy* Non-concordant empirical therapy** p-value
Age (years)
Mean±SD 55.1±25.5 56.4±26.1 0.57
Median 59 63
Male gender 209/405 (51.6%) 100/161 (62.1%) 0.02
Organism
Escherichia coli 152/565 (26.9%) 49/223 (22%) 0.17
Klebsiella pneumoniae 90/565 (15.9%) 31/223 (13.9%) 0.51
Staphylococcus aureus 73/565 (12.9%) 16/223 (7.2%) 0.02
Pseudomonas aeruginosa 46/565 (8.1%) 28/223 (12.6%) 0.05
Acinetobacter baumannii 25/565 (4.4%) 44/223 (19.7%) <0.001
Clinical features
Community-acquired infection 342/565 (60.5%) 94/223 (42.3%) <0.001
Hospital-acquired infection 224/565 (39.6%) 139/223 (62.3%) <0.001
Primary bacteremia 186/565 (32.9%) 51/223 (22.9%) 0.006
Secondary bacteremia 323/565 (57.2%) 156/223 (70.0%) <0.001
Sepsis 324/565 (57.3%) 118/223 (52.9%) 0.27
Length of hospital stay (days)
Mean±SD 32.9±38.8 41.3±33.5 0.02
Median 20 31
Clinical response at end of treatment
Response 294/462 (63.6%) 103/223 (46.2%) <0.001
Superimposed infection 78/462 (16.9%) 46/223 (20.6%) 0.23
Death 90/462 (19.5%) 74/223 (33.2%) <0.001
In-hospital mortality 134/462 (29.0%) 110/223 (49.3%) <0.001
https://doi.org/10.1371/journal.pone.0190132.t006
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The cost of hospitalization for each patient with bacteremia was retrieved from the hospital
database of the Computer Unit and the Financial Department of Siriraj Hospital. The annual
cost of hospitalizations for patients with bacteremia was estimated from the cost of hospitaliza-
tions for patients with bacteremia during the study period for eight months. The estimated
total annual cost of hospitalizations for patients with bacteremia was US$ 10,854,132, of which
US$ 5,409,816 was spent for patients with antibiotic-non-resistant bacteremia (US$ 8,614/
admission), and US$ 5,444,316 was spent for patients with antibiotic-resistant bacteremia (US
$ 15,379/admission). The estimated annual cost of hospitalizations for patients with commu-
nity-acquired bacteremia was US$ 2,088,260 (US$ 4,725/admission) and hospital-acquired
bacteremia was US$ 8,765,872 (US$ 16,233/admission).
Discussion
The manual for early implementation of GLASS in human infections recommends blood,
urine, feces, and urethral and cervical swabs as priority specimens; and E.coli, K.pneumoniae,
A.baumannii, S.aureus, S.pneumoniae, Salmonella spp., Shigella spp., and N.gonorrhoeae as pri-
ority bacteria. However, GLASS implementation at Siriraj Hospital included collection of spu-
tum because respiratory tract infection is very common infection in hospitalized patients [9,
10]. Furthermore, the interpretation of sputum culture results is challenging, regardless of
whether the isolated organism is causative agent, colonizer, or contaminant. We did not
include urogenital swabs for gonococcal culture, because these specimens are very uncommon.
We also collected P.aeruginosa because it is one of the most common causative bacteria, espe-
cially in HAI [9, 10].
A key feature of GLASS is that patient clinical data and microbiological data are combined.
We recognize that many types of relevant patient clinical data are often not included in the
information submitted to the laboratory along with the clinical sample. Moreover, new and
important patient clinical data will become available after the clinical sample has been sent to
the laboratory. As a result, the report of the culture result is usually incomplete and limited in
Table 8. In-hospital mortality of patients with priority pathogens as the cause of bacteremia.
Bacteria Mortality p-value
Antibiotic-resistant
bacteriaa
Antibiotic-non-resistant
bacteria
Escherichia coli 23/106 (21.7%) 18/100 (18.0%) 0.51
Klebsiella pneumoniae 23/45 (51.1%) 22/65 (33.8%) 0.07
Other Enterobacteriaceae 3/8 (37.5%) 12/43 (27.9%) 0.58
Pseudomonas aeruginosa 10/21 (47.6%) 19/47 (40.4%) 0.58
Acinetobacter baumannii 38/57 (66.7%) 3/24 (12.5%) <0.001
Salmonella spp. 0/2 (0%) 1/2 (50.0%) 0.25
Staphylococcus aureus 9/16 (56.3%) 13/47 (27.7%) 0.04
Coagulase-negative Staphylococcus
spp.
1/14 (7.1%) - -
Enterococcus faecium 6/9 (66.7%) 12/20 (60.0%) 0.73
Streptococcus pneumoniae 0/1 (0%) 0/3 (0%) -
Overall in-hospital mortality 113/279 (40.5%) 100/351 (28.5%) <0.001
a Carbapenem-resistant or third-generation cephalosporin-resistant E.coli, K.pneumoniae, and other
Enterobacteriaceae; carbapenem-resistant P.aeruginosa; carbapenem-resistant A.baumannii;
fluoroquinolone-resistant Salmonella spp.; MRSA; MRCNS; vancomycin-resistant E.faecium; and, penicillin-
non-susceptible S.pneumoniae
https://doi.org/10.1371/journal.pone.0190132.t008
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value, because it does not include or take into account these important pieces of missing data.
Many clinical data were collected from patients in our study using a locally developed user-
friendly web application program that could be installed in a smart phone and conveniently
used in patient care areas. Supplementary information that was collected included source of
infection, severity of infection, empirical and specific antibiotic therapy, clinical outcomes of
infection, patient mortality, and cost of hospitalization. This additional data was important to
understand the epidemiology of bacteremia at our center, to enhance our ability to develop
more appropriate local antibiotic guidelines, and to estimate health and economic burden of
bacteremia caused by AMR bacteria.
The reported blood culture contamination rate of 3.5% was higher than the acceptable tar-
get rate of less than 3% [11]. CNS was the most common blood culture contaminant, and it
accounted for 19% of positive blood culture specimens, but it was less than 32% of CNS
among all isolated bacteria in the 2016 annual report of the National Antimicrobial Resistance
Surveillance Centre, Thailand [12]. The rate of blood culture contamination is a recommended
indicator of health care quality. We, therefore, intend to implement additional measures to
reduce the rate of contaminants in blood cultures. Our study revealed that 15.1% of CNS iso-
lated from blood specimens were causative bacteria based on patient clinical data. Therefore,
information relating to clinical features of patients with positive blood culture for CNS was
extremely important for determining if CNS was a causative agent that required antibiotic
therapy. This observation emphasized the importance and value of collecting clinical data in
addition to demographic data recommended in GLASS manual. CNS that caused infection
tended to be less resistant to antibiotics than CNS that was contaminant. This observation sug-
gested that bacteria isolated from sputum and urine samples that was colonizer might be more
resistant to antibiotics than isolated bacteria that was the cause of infection.
We would have been unable to determine if isolated bacteria was primary bacteremia, sec-
ondary bacteremia, or CLABSI unless the clinical features of patients with positive blood cul-
tures were taken into account. Classification of these 3 categories of bacteremia was necessary,
because the bacteria that caused different types of bacteremia were different, and each type of
bacteremia required a different regimen of empirical antibiotic therapy. If all bacteria that
cause all types of bacteremia would have been combined and those data were used for develop-
ing empirical antibiotic guidelines for patients with bacteremia, many patients with different
types of bacteremia would have received inappropriate antibiotic regimens.
Differentiation between bacteremia in CAI and HAI was necessary since the types of causa-
tive bacteria, the antibiotic susceptibility profiles of bacteria, and the clinical outcomes of CAI
and HAI were significantly different. Important data including hospitalization at other health-
care facilities >2 days within 90 days, healthcare-associated conditions, and duration of cur-
rent hospitalization >2 days were needed to determine if bacteremia was HAI. We found that
if duration from date of hospitalization to date of blood culture collection of2 days was used
to classify bacteremia as CAI, at least 10% of patients with HAI would have been classified as
CAI. Misclassification of some bacteremic episodes as CAI instead of HAI resulted in signifi-
cantly higher prevalence of antibiotic resistance to causative bacteria, such as prevalence of
community-acquired MRSA from 0% to 9% and prevalence of ceftriaxone-resistant E.coli and
K.pneumoniae from 19.3% to 38.5%.
Observations from our study confirmed the results of previous studies that E.coli, K.pneu-
moniae, S.aureus, A.baumannii, and P.aeruginosa were common causative agents of bacter-
emia, and that the clinical outcomes of bacteremia due to antibiotic-resistant bacteria were
unfavorable [1, 9, 10, 13–19]. However, our study results revealed additional important details
about bacteremia, such as the sources of secondary bacteremia, sepsis status in bacteremia
patients, and antibiotic susceptibility of community-acquired and hospital-acquired bacterial
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blood isolates–all of which will be useful for managing patients with suspected bacteremia in
the future.
We found no significant differences in antibiotic susceptibility between non-duplicate iso-
lates and duplicate isolates among E.coli, K.pneumoniae, Salmonella spp., A.baumannii, P.aeru-
ginosa, E.faecalis, E.faecium, S.aureus, CNS, and S.pneumoniae. This could be due to the fact
that most patients had only one episode of bacteremia, each episode of bacteremia usually had
one type of bacteria, and most isolated bacteria were causative agents. It is anticipated that dif-
ferences in antibiotic susceptibility between non-duplicate and duplicate isolates of bacteria
from other clinical specimens commonly colonized with organisms (e.g., sputum and urine)
should be observed similar to our finding of more antibiotic resistance in CNS isolates that
were contaminants than CNS isolates that were the cause of infection.
Many metrics of AMR surveillance according to GLASS protocol are presented in our
results. However, some recommended metrics could not be computed, such as the number of
blood cultures per 100,000 inhabitants. This is because many patients who receive medical
care from Siriraj Hospital are not residents of Siriraj Hospital catchment areas. Siriraj Hospital
is a national tertiary referral hospital and we receive and treat patients that are referred from
across Thailand.
Based on our findings, GLASS was superior to the laboratory-based surveillance for blood
culture specimens in patients with bacteremia. Although GLASS consumed more time and
resources than the laboratory-based surveillance system, the data derived from GLASS was
more useful for developing antibiotic guidelines for patients suspected of having bacteremia.
Data derived from GLASS are also valuable for estimating and monitoring the antimicrobial
consumption and usage, and health and economic burden of AMR. Furthermore, the results
from GLASS can be used to estimate and monitor a drug resistance index [20]. Given that the
GLASS that we implemented at Siriraj Hospital exceeded the minimum recommended criteria
set forth in GLASS manual, it may be difficult to fully and permanently implement this system
in the near term on institution-wide basis. Therefore, we may activate GLASS for one 6-month
period every other year because the types of causative agents of infections and their antibiotic
susceptibility should not have dramatic changes over a short period of time. Another alterna-
tive for ideal implementation of GLASS would require responsible personnel who will send
the clinical specimen for culture to provide all relevant patient clinical data along with request
for culture of clinical specimen.
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